Drugmaker Watson Pharmaceuticals is facing a legal battle over its plans to market a generic version of Abbot Laboratories’ Simcor, it has been revealed.
The challenge came after Watson filed an application with the Food and Drug Administration to market simvastatin and niacin extended-release tablets.
The treatment is used in patients with high cholesterol, especially where non-pharmaceutical measures have been unsuccessful.
Abbot hopes to prevent Watson from commercialising its version of the drug before the expiration of eight patents covering Simcor, the last of which expires in 2018, according to FDA records.
The case puts a stay of FDA approval of two-and-half years or until the two companies resolve the disagreement in court.
Copyright Press Association 2010